SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction


  • Org Study ID: NCI-2012-01040
  • Secondary ID: NCI-2012-01040,NA_00052587,NCI-2013-01545,CDR0000737061,J11105,9008,9008,U01CA132123,U01CA062505,U01CA069912,U01CA070095,UM1CA186644,UM1CA186686,UM1CA186689,UM1CA186690,UM1CA186691,UM1CA186716,UM1CA186717,ZIABC011078
  • NCT ID: NCT01638533
  • NCT Alias:
  • Sponsor: National Cancer Institute (NCI) - NIH
  • Source: National Cancer Institute (NCI)

Brief Summary

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

Detailed Description


PRIMARY OBJECTIVES:

I. To establish the safety and tolerability of romidepsin given on days 1, 8, and 15 of a 28
day cycle to patients with varying degrees of liver dysfunction (mild, moderate and severe).

II. To establish the maximum tolerated dose (MTD) and appropriate dosing recommendations for
romidepsin in such patients.

III. To characterize the pharmacokinetics (PK) of romidepsin in patients with varying degrees
of liver dysfunction.

SECONDARY OBJECTIVES:

I. To explore correlations of the Child-Pugh classification of liver dysfunction with the
observed toxicities and plasma PK of romidepsin administration.

II. To document any preliminary evidence of antitumor activity at tolerable doses of
romidepsin in patients with varying degrees of liver dysfunction.

OUTLINE: This is a dose-escalation study.

Patients receive romidepsin intravenously (IV) over 4 hours on days 1, 8, and 15. Courses
repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.

Overal Status Start Date Phase Study Type
Recruiting June 12, 2012 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Maximum tolerated dose of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0

Primary Outcome 1 - Time Frame: 28 days

Primary Outcome 2 - Measure: Dose-limiting toxicity of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0

Primary Outcome 2 - Time Frame: 28 days

Primary Outcome 3 - Measure: Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method

Primary Outcome 3 - Time Frame: 0, 1, 2, 3, 4, 4.25, 4.5, 5, 6, 8, 10, 24, and 48 hours after initiation of the infusion on day 1

Condition:

  • Glioma
  • Lymphoma
  • Metastatic Malignant Solid Neoplasm
  • Neuroendocrine Neoplasm
  • Recurrent Adult Soft Tissue Sarcoma
  • Recurrent Bladder Carcinoma
  • Recurrent Breast Carcinoma
  • Recurrent Chronic Lymphocytic Leukemia
  • Recurrent Colorectal Carcinoma
  • Recurrent Head and Neck Carcinoma
  • Recurrent Lung Carcinoma
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Melanoma
  • Recurrent Pancreatic Carcinoma
  • Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Recurrent Prostate Carcinoma
  • Recurrent Renal Cell Carcinoma
  • Recurrent Thyroid Gland Carcinoma
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  • Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Stage III Breast Cancer AJCC v7
  • Stage III Colorectal Cancer AJCC v7
  • Stage III Cutaneous Melanoma AJCC v7
  • Stage III Lung Cancer AJCC v7
  • Stage III Pancreatic Cancer AJCC v6 and v7
  • Stage III Prostate Cancer AJCC v7
  • Stage III Renal Cell Cancer AJCC v7
  • Stage III Soft Tissue Sarcoma AJCC v7
  • Stage IIIA Breast Cancer AJCC v7
  • Stage IIIA Colorectal Cancer AJCC v7
  • Stage IIIA Cutaneous Melanoma AJCC v7
  • Stage IIIB Breast Cancer AJCC v7
  • Stage IIIB Colorectal Cancer AJCC v7
  • Stage IIIB Cutaneous Melanoma AJCC v7
  • Stage IIIC Breast Cancer AJCC v7
  • Stage IIIC Colorectal Cancer AJCC v7
  • Stage IIIC Cutaneous Melanoma AJCC v7
  • Stage IV Breast Cancer AJCC v6 and v7
  • Stage IV Colorectal Cancer AJCC v7
  • Stage IV Cutaneous Melanoma AJCC v6 and v7
  • Stage IV Lung Cancer AJCC v7
  • Stage IV Pancreatic Cancer AJCC v6 and v7
  • Stage IV Prostate Cancer AJCC v7
  • Stage IV Renal Cell Cancer AJCC v7
  • Stage IV Soft Tissue Sarcoma AJCC v7
  • Stage IVA Colorectal Cancer AJCC v7
  • Stage IVB Colorectal Cancer AJCC v7
  • Unresectable Solid Neoplasm

Eligibility

Criteria:
Inclusion Criteria:

- Patients must have histologically or cytologically confirmed (at original diagnosis or
subsequent recurrence or progression) lymphoma, chronic lymphocytic lymphoma (CLL) or
solid tumor; patients with lymphoma or CLL must have radiologically or clinically
evaluable disease, and be refractory to standard therapy as defined by relapse within
6 months of last treatment (see note below); patients with solid tumors must have
radiologically or clinically evaluable disease that is metastatic, unresectable,
progressive, or recurrent, and for which standard curative measures do not exist or
are no longer effective

- Patients with a liver mass, raised alpha-fetoprotein level (>= 500 ng/mL) and
positive serology for hepatitis, consistent with a diagnosis of hepatocellular
carcinoma will be eligible without the need for pathologic confirmation of the
diagnosis

- Patients with prostate cancer, renal cell cancer, neuroendocrine tumors, lung
cancer, colorectal cancers, soft tissue sarcomas, glioma and thyroid cancer are
excluded in the normal and mild cohorts due to a lack of efficacy in these tumor
types in phase 2 studies; patients with breast, pancreatic, bladder, head and
neck cancers, as well as melanoma and other malignancies are eligible

- Note: patients with prostate cancer, renal cell cancer, lung cancer, colorectal
cancers, soft tissue sarcomas, glioma and thyroid cancer are allowed to enroll in
the moderate and severe cohorts provided the patients:

- Sign a separate consent form which outlines the lack of efficacy observed in
prior studies

- Are consented to the study by a protocol-specified designee who is not their
longitudinal oncologist; patients with neuroendocrine tumors are still
excluded from the moderate and severe cohorts

- Note: as romidepsin is approved for patients with relapsed or refractory
peripheral T-cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL), these
patients would be eligible WITHOUT the requirement of having 'relapsed within 6
months of last treatment'

- Life expectancy of > 3 months

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

- Hemoglobin >= 9 g/dL (transfusions and/or erythropoietin are permitted)

- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

- Platelets >= 100 x 10^9/L (or platelet count >= 30 x 10^9 cells/L in patients with
lymphoma or CLL if bone marrow disease involvement is documented)

- Creatinine =< twice upper limit institutional normal

- Patients with abnormal liver function will be eligible and will be grouped according
to the criteria below

- Group A (normal hepatic function)

- Bilirubin =< upper limit of normal (ULN) and aspartate aminotransferase
(AST) =< ULN

- Group B (mild hepatic dysfunction)

- B1: bilirubin =< ULN and AST > ULN

- B2: bilirubin > ULN but =< 1.5 x ULN and any AST

- Group C (moderate hepatic dysfunction)

- Bilirubin > 1.5 x ULN to =< 3 x ULN and any AST

- Group D (severe hepatic dysfunction)

- Bilirubin > 3 x ULN and up to investigators discretion and any AST

- Patients with active hemolysis should be excluded; no distinction will be made
between liver dysfunction due to metastases and liver dysfunction due to other
causes; registration laboratory investigations will be used to assign a patient
to a hepatic function group; liver function tests should be repeated within 24
hours prior to starting initial therapy and may result in the patients' group
assignment being altered if different to registration test results

- Patients with brain metastases who require corticosteroids or non-enzyme inducing
anticonvulsants must be on a stable dose of corticosteroids and seizure free for 1
month prior to enrollment; patients with known brain metastases should have completed
brain irradiation (whole brain or gamma knife) more than 4 weeks before starting the
protocol; patients on enzyme inducing anticonvulsants are not eligible; note that
patients should have had their steroids tapered to low dose (i.e. < 1.5 mg of
dexamethasone/day) due to the potential for higher dexamethasone doses to induce
CYP3A4

- Patients with biliary obstruction for which a stent has been placed are eligible,
provided the shunt has been in place for at least 10 days prior to the first dose of
romidepsin and the liver function has stabilized; two measurements at least 2 days
apart that put the patient in the same hepatic dysfunction stratum will be accepted as
evidence of stable hepatic function; there should be no evidence of biliary sepsis

- Eligibility of patients receiving any medications or substances known to affect or
with the potential to affect the activity or PK of romidepsin will be determined
following review of their case by the site principal investigator

- Patients treated with any of the medications prohibited must discontinue their
use at least 7 days prior to the first dose of romidepsin; certain other agents
that interact with the CYP3A4 system may be used with caution

- Women of childbearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and for
the duration of study participation; should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician
immediately; note: since romidepsin binds to the estrogen receptor, the effectiveness
of estrogen containing contraceptives may be reduced

- Human immunodeficiency virus (HIV)-positive patients who are not receiving: agents
with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals
(nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine,
emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor
(PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir,
maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients
should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause
of hepatic dysfunction is unknown, the patient should be worked up for other viral
causes of hepatitis and their eligibility determined after consultation with the
principal investigator

- Patients who have received prior romidepsin use are eligible

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had (prior to entering the study): major surgery and
biologic/antibody therapies (including immunotherapies) are not permitted within 4
weeks of romidepsin administration; anti-cancer therapy including chemotherapy,
radiotherapy, hormonal (with the exception of hormones for thyroid conditions), and
other investigational agents will not be allowed within 14 days or five (5) half-lives
(whichever is longer) prior to the first dose of romidepsin (6 weeks for nitrosoureas
or mitomycin C); additionally, participants must have recovered to less than grade 2
clinically significant adverse effect(s)/toxicity(ies) of the previous therapy, with
the exception of alopecia, unless approved by the principal investigator

- Patients with prostate cancer, renal cell cancer, neuroendocrine tumors, lung cancer,
colorectal cancers, soft tissue sarcomas, glioma, and thyroid cancer are excluded in
the normal and mild cohorts due to a lack of efficacy in these tumor types in phase 2
studies; patients with prostate cancer, renal cell cancer, lung cancer, colorectal
cancers, soft tissue sarcomas, glioma and thyroid cancer are allowed to enroll in the
moderate and severe cohorts only; patients with neuroendocrine tumors are still
excluded from the moderate and severe cohorts

- Patients may not be receiving any other investigational agents

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to romidepsin, including cyclic tetrapeptide compounds

- Concurrent medications associated with a known risk of corrected QT interval (QTc)
prolongation and/or Torsades de Pointes are not allowed within 2 weeks of initiation
of study treatment; those medications listed as a possible risk for causing QTc
prolongation and Torsades de Pointes will be allowed, although if an alternative
medication can be substituted, that would be preferable; granisetron is an acceptable
antiemetic on this study, but if a patient must take ondansetron, they may NOT take
any other concomitant agents which might impact their QTc

- Thiazolidinedione agents such as rosiglitazone and pioglitazone are not permitted

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, or psychiatric illness/social situations that would limit compliance with
study requirements

- Patients with current evidence of significant cardiovascular disease (New York Heart
Association class III or IV cardiac disease), symptomatic congestive heart failure,
dilated/hypertrophic or restrictive cardiomyopathy, myocardial infarction (within the
past 6 months), unstable angina, unstable arrhythmia or a need for anti-arrhythmic
therapy (use of medications for rate control for atrial fibrillation is allowed such
as calcium channel blockers and beta-blockers, if stable medication for at least last
month prior to initiation of romidepsin treatment and medication not listed as causing
Torsades de Pointes), or evidence of acute ischemia on electrocardiogram (ECG); marked
baseline prolongation of QT/QTc interval, e.g., repeated demonstration of a QTc
interval > 450 msec*; long QT syndrome; the required use of concomitant medication
that may cause Torsades de Pointes or may cause a significant prolongation of the QTc

- Note: due to difficulties assessing QTc in patients with heart block, they may be
eligible if deemed safe by a cardiologist; if a patient must take ondansetron as
their antiemetic, their QTc may NOT be over 450 (no exception for patients with
heart block)

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with this drug

- Warfarin is not permitted
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Roisin Connolly

Role: Principal Investigator

Affiliation: JHU Sidney Kimmel Comprehensive Cancer Center LAO

Locations

Facility Status Contact
City of Hope Comprehensive Cancer Center
Duarte, California 91010
United States
Suspended
University of California Davis Comprehensive Cancer Center
Sacramento, California 95817
United States
Suspended
City of Hope South Pasadena
South Pasadena, California 91030
United States
Recruiting Stephen C. Koehler
626-396-2900
skoehler@cohmg.com
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
United States
Suspended
University of Chicago Comprehensive Cancer Center
Chicago, Illinois 60637
United States
Active, not recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland 21287
United States
Recruiting Roisin M. Connolly
410-955-8804
jhcccro@jhmi.edu
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland 20892
United States
Suspended
National Institutes of Health Clinical Center
Bethesda, Maryland 20892
United States
Active, not recruiting
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan 48201
United States
Suspended
Mayo Clinic
Rochester, Minnesota 55905
United States
Recruiting Paul Haluska
507-284-2511
haluska.paul@mayo.edu
Case Western Reserve University
Cleveland, Ohio 44106
United States
Active, not recruiting
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania 17033-0850
United States
Active, not recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania 19107
United States
Active, not recruiting
University of Wisconsin Hospital and Clinics
Madison, Wisconsin 53792
United States
Recruiting Roisin M. Connolly
410-614-9217
rconnol2@jhmi.edu
University Health Network-Princess Margaret Hospital
Toronto, Ontario M5G 2M9
Canada
Recruiting Lillian L. Siu
416-946-4501
clinical.trials@uhn.on.ca